OncoMatch/Leukemia — Chronic Myeloid (CML)/ABL1 kinase domain mutation
Leukemia — Chronic Myeloid (CML)ABL1 kinase domain mutation Clinical Trials
ABL1 kinase domain mutations — most notably T315I — are the primary mechanism of TKI resistance in CML, conferring varying degrees of resistance to first-, second-, and third-generation inhibitors. T315I is resistant to most ATP-competitive TKIs and is targetable with ponatinib and asciminib (STAMP inhibitor), though compound mutations can limit activity. Trials investigate mutation-specific treatment sequencing, asciminib combinations, and novel allosteric ABL1 inhibitors.
Top recruiting ABL1 kinase domain mutation Leukemia — Chronic Myeloid (CML) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd.
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Terns, Inc.
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Kartos Therapeutics, Inc.
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
More ABL1 kinase domain mutation Leukemia — Chronic Myeloid (CML) trials
6 international trials (no US sites)
Browse other molecular targets with active Leukemia — Chronic Myeloid (CML) trials.